Cytokinetics (NASDAQ:CYTK) CEO Robert Blum Sells 7,931 Shares

Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert Blum sold 7,931 shares of the business’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $60.72, for a total value of $481,570.32. Following the transaction, the chief executive officer directly owned 391,673 shares in the company, valued at $23,782,384.56. This trade represents a 1.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Cytokinetics Stock Up 2.9%

Shares of CYTK opened at $64.20 on Wednesday. Cytokinetics, Incorporated has a 52-week low of $29.31 and a 52-week high of $70.98. The stock has a fifty day simple moving average of $64.02 and a two-hundred day simple moving average of $60.08. The company has a market capitalization of $7.91 billion, a PE ratio of -9.83 and a beta of 0.56.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, missing the consensus estimate of ($1.48) by ($0.02). The firm had revenue of $17.76 million for the quarter, compared to analysts’ expectations of $8.02 million. During the same quarter last year, the firm posted ($1.26) earnings per share. The company’s revenue was up 4.9% on a year-over-year basis. As a group, equities analysts anticipate that Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cytokinetics

Institutional investors have recently bought and sold shares of the company. Lisanti Capital Growth LLC acquired a new position in shares of Cytokinetics in the third quarter valued at approximately $2,697,000. Sanders Morris Harris LLC acquired a new stake in Cytokinetics during the 3rd quarter worth approximately $1,182,000. Y Intercept Hong Kong Ltd purchased a new position in Cytokinetics in the 3rd quarter valued at approximately $1,359,000. Moody Aldrich Partners LLC acquired a new position in shares of Cytokinetics in the third quarter worth $4,532,000. Finally, Norges Bank acquired a new position in shares of Cytokinetics in the second quarter worth $39,122,000.

Cytokinetics News Summary

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Earnings call frames a “high‑stakes” commercial launch for Cytokinetics’ new heart drug — the company is shifting from development to commercialization, which can materially expand revenue if uptake meets expectations. This launch-phase narrative is the primary driver of bullish sentiment. Cytokinetics Earnings Call Marks High-Stakes Launch Phase
• Positive Sentiment: An insider exercised options worth roughly $920k+ as the heart drug hit the market — often interpreted by investors as a signal the commercial program is proceeding and that management/insiders are monetizing value created by the launch. Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market
• Neutral Sentiment: Short‑interest data reported for early March shows “0” shares — this appears to be a data error or placeholder rather than meaningful short activity, so it should not be interpreted as a shift in bearish positioning.
• Negative Sentiment: Several insiders sold shares on March 9 (CEO Robert Blum sold 7,931 shares at ~$60.72; EVP Fady I. Malik sold 2,907 shares; EVP Andrew Callos sold 2,582 shares). While each insider still holds substantial positions (sales reduced holdings by low single-digit percentages), such disclosures can be read negatively by some investors as profit-taking after the launch. CEO Form 4: CEO Form 4 — EVP Malik Form 4: Malik Form 4 — EVP Callos Form 4: Callos Form 4

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Cytokinetics in a report on Wednesday, January 21st. Barclays started coverage on Cytokinetics in a research report on Wednesday, January 28th. They issued an “overweight” rating and a $87.00 price objective for the company. Leerink Partners restated an “outperform” rating on shares of Cytokinetics in a research report on Tuesday. Needham & Company LLC increased their price target on Cytokinetics from $84.00 to $85.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Finally, Royal Bank Of Canada raised their price objective on Cytokinetics from $95.00 to $101.00 and gave the stock an “outperform” rating in a research report on Friday, February 20th. Seventeen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $89.00.

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.